Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female patients~* aged 18 and older who meet criteria for fibromyalgia as defined by the American College of Rheumatology~* have a score of at least 4 on the average pain item of the Brief Pain Inventory (BPI) (modified short form) at visits 1 and 2~* all females must test negative for pregnancy at the time of enrollment~* have a degree of understanding such that the patient can provide informed consent, complete protocol required assessments and communicate intelligibly with the investigator and study coordinator.~Exclusion Criteria:~* have pain symptoms related to traumatic injury, structural rheumatic disease, or regional rheumatic disease that will interfere with interpretation of outcome measures~* have regional pain syndrome, multiple surgeries or failed back syndrome~* have confirmed current or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infectious arthritis, or an autoimmune disease (i.e. systemic lupus erythematosus)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): 60-120 mg, oral, every day, 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): oral, daily, 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).